it may reduce the effectiveness of oral contraceptives during initiation/dose escalation
Use this time to experiment with options that feel good and don't create crashes
LeWine, MD, Chief Medical Editor, Harvard Health Publishing
Tirzepatide is a 39amino acid dual incretin receptor agonist that activates both GLP1 and GIP receptors, enhancing glucosedependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite [1] [2]
Preclinical findings may help researchers study tissue repair pathways, but they should not be interpreted as proof of human benefit
While extremely rare with proper subcutaneous injection technique, patients should seek immediate medical attention if they experience acute chest pain, sudden shortness of breath, or neurological symptoms after an injection, as these could indicate an adverse reaction requiring medical evaluation